Search
Botanix executive director Matthew Callahan.

Botanix makes ASX debut

Medical dermatology company Botanix Pharmaceuticals has enjoyed healthy gains on its first day of trading on the ASX, after completing a reverse takeover of Bone Medical.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 31/03/20

1 year TSR5 year TSR
34thResApp Health127%85%
264thMustera Property Group-3%2%
338thProteomics International Laboratories-17%
793rdBotanix Pharmaceuticals-80%-2%
798thDXN-82%
669 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

21/02/20
$0 Other
11/12/19
$27k Other
18/07/19
$0 Issued
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

93rd↑Botanix Pharmaceuticals$4.7m
101st↓Mustera Property Group$3.1m
104th↑ResApp Health$2.7m
106th↑Proteomics International Laboratories$2.7m
108th-DXN$2.6m
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®